Iovance Biotherapeutics Inc (STU:2LB)
€ 10.415 0.26 (2.56%) Market Cap: 3.20 Bil Enterprise Value: 2.89 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 39/100

Iovance Biotherapeutics Inc Melanoma Treatment Landscape Transcript

Jun 26, 2023 / 09:00PM GMT
Release Date Price: €7.11 (-3.34%)
Operator

Welcome to the Iovance Biotherapeutics Virtual Key Opinion Leader Roundtable. My name is Latif, and I will be your operator for today's call. (Operator Instructions) Please note that this conference is being recorded. I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance.

Sara, you may begin.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good afternoon, and thank you for joining us. Speaking on today's call, Dr. Brian Gastman, our Executive Vice President of Regulatory Affairs, will provide a brief summary about our TIL therapy lifileucel and moderated discussion with our guest panelists who are key opinion leaders in the field of melanoma and TIL therapy. Then we will open the call for questions from the audience.

We encourage everyone with questions to take advantage of the time with the KOLs to learn more about their perspective on the melanoma treatment landscape and TIL therapy. Additional Iovance team

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot